EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern

Hattan Boshah iD, Faris Samkari, Alexander U Valle-Pérez iD, Sarah M Alsawaf, Ali H Aldoukhi iD, Panayiotis Bilalis iD, Salwa A Alshehri iD, Hepi H Susapto iD, Charlotte A E Hauser iD

BioMed Research International · 2023

DOI: 10.1155/2023/3892370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2023. Verfasst von Hattan Boshah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Nanomedicine, Division of Biological and Environmental Science and Engineering (BESE), King Abdullah University of Science and Technol…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdullah University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has greatly affected all aspect of life. Although several vaccines and pharmaceuticals have been developed against SARS‐CoV‐2, the emergence of mutated variants has raised several concerns. The angiotensin‐converting enzyme (ACE2) receptor cell entry mechanism of this virus has not changed despite the vast mutation in emerging variants. Inhibiting the spike protein by which the virus identifies the host ACE2 receptor is a promising therapeutic countermeasure to keep pace with rapidly emerging variants. Here, we synthesized two ACE2‐derived peptides, P1 and P25, to target and potentially inhibit SARS‐CoV‐2 cell entry. These peptides were evaluated in vitro using pseudoviruses that contained the SARS‐CoV‐2 original spike protein, the Delta‐mutated spike protein, or the Omicron spike protein. An in silico investigation was also done for these peptides to evaluate the interaction of the synthesized peptides and the SARS‐CoV‐2 variants. The P25 peptide showed a promising inhibition potency against the tested pseudoviruses and an even higher inhibition against the Omicron variant. The IC 50 of the Omicron variant was 60.8 μ M, while the IC 50 s of the SARS‐CoV‐2 original strain and the Delta variant were 455.2 μ M and 546.4 μ M, respectively. The in silico experiments also showed that the amino acid composition design and structure of P25 boosted the interaction with the spike protein. These findings suggest that ACE2‐derived peptides, such as P25, have the potential to inhibit SARS‐CoV‐2 cell entry in vitro. However, further in vivo studies are needed to confirm their therapeutic efficacy against emerging variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2COVID-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusPeptidesProtein Binding

Substanzen

Angiotensin-Converting Enzyme 2Spike Glycoprotein, CoronavirusPeptidesspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Laboratory for Nanomedicine, Division of Biological and Environmental Science and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
  • KAUST Smart Health Initiative (KSHI), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
  • Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
  • Red Sea Research Center (RSRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia.
  • Department of Biochemistry, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia.

ORCID-Profile: Hattan Boshah, Alexander U Valle-Pérez, Ali H Aldoukhi, Panayiotis Bilalis, Salwa A Alshehri, Hepi H Susapto, Charlotte A E Hauser

Förderung

  • King Abdullah University of Science and Technology

Zitieren

APA

Boshah, H., Samkari, F., Valle-Pérez, A. U., Alsawaf, S. M., Aldoukhi, A. H., Bilalis, P., Alshehri, S. A., Susapto, H. H., & Hauser, C. A. E. (2023). Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern. BioMed Research International. https://doi.org/10.1155/2023/3892370

Vancouver

Boshah H, Samkari F, Valle-Pérez AU, Alsawaf SM, Aldoukhi AH, Bilalis P, et al. Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern. BioMed Research International. 2023. doi:10.1155/2023/3892370

BibTeX
@article{Boshah2023,
  author = {Boshah, Hattan and Samkari, Faris and Valle-Pérez, Alexander U and Alsawaf, Sarah M and Aldoukhi, Ali H and Bilalis, Panayiotis and Alshehri, Salwa A and Susapto, Hepi H and Hauser, Charlotte A E},
  title = {Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern},
  journal = {BioMed Research International},
  year = {2023},
  doi = {10.1155/2023/3892370}
}
Kostenlos starten →